Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Insulin Lispro Formulations
NCT02111083Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin lispro in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline, Maximum Serum Insulin Concentration and 1 more. Started May 2014; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02111083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111083.